Bharat Immunological & Biological Corporation
BHARATIMMUNOLOGICALSBIOLOGICALSCORPORATIONLTD NSE
Bharat Immunological & Biological Corporation
HealthcareNSE: BHARATIMMUNOLOGICALSBIOLOGICALSCORPORATIONLTD BSE: BIBCL Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹64.75 Cr
Volatility
Moderate
P/E Ratio
-3.6
EBITDA
₹-15.70 Cr
Return on Equity
-19.43%
Debt to Equity
0.8
Book Value
₹-7.54
EPS
₹0
52W High
₹22.61
52W Low
₹14.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 0.83 times its book value
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.09% over past five years.
- Company has a low return on equity of -22.7% over last 3 years.
- Debtor days have increased from 39.6 to 114 days.
Growth Rate
Revenue Growth
-40.38% lower than
3Y
Net Income Growth
94.32% higher than
3Y
Cash Flow Change
126% higher than
3Y
ROE
134% higher than
3Y
ROCE
357% higher than
3Y
EBITDA Margin (Avg.)
577% higher than
3Y
Quarterly Results
| Particulars | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.36 | 25.2 | 15.62 | 14.22 | 24.7 | 17.43 | 22.04 | 10.48 | 26.48 | 0 | 7.65 | 0 | 0 |
| Expenses | 29.86 | 27.47 | 31.54 | 13.18 | 28.19 | 16.41 | 25.71 | 15.31 | 28.98 | 4.72 | 11.67 | 4.31 | 4.68 |
| Operating Profit | -4.5 | -2.27 | -15.92 | 1.04 | -3.49 | 1.02 | -3.67 | -4.83 | -2.5 | -4.72 | -4.02 | -4.31 | -4.68 |
| OPM % | -17.74% | -9.01% | -101.92% | 7.31% | -14.13% | 5.85% | -16.65% | -46.09% | -9.44% | — | -52.55% | — | — |
| Other Income | 0.14 | 1.2 | 9.08 | 0.25 | 0.22 | 0.12 | 0.59 | 0.14 | 0.32 | 0.1 | 0.49 | 0.1 | 0.16 |
| Interest | 1.17 | 1.3 | 1.22 | 1.16 | 1.23 | 1.54 | 1.68 | 1.58 | 1.74 | 1.67 | 2.06 | 1.72 | 2.09 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 |
| PBT | -5.59 | -2.43 | -8.12 | 0.07 | -4.56 | -0.44 | -4.81 | -6.31 | -3.96 | -6.33 | -5.68 | -5.96 | -6.64 |
| Tax % | -30.77% | -21.81% | -19.46% | -2642.86% | 105.26% | -25% | -11.02% | -20.76% | -22.22% | -26.07% | -31.69% | -23.15% | -26.05% |
| Net Profit | -3.87 | -1.89 | -6.53 | 1.93 | -9.36 | -0.33 | -4.28 | -5 | -3.08 | -4.68 | -3.88 | -4.59 | -4.92 |
| EPS in Rs | -0.9 | -0.44 | -1.51 | 0.45 | -2.17 | -0.08 | -0.99 | -1.16 | -0.71 | -1.08 | -0.9 | -1.06 | -1.14 |
Profit & Loss
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 |
| Expenses | 41 | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 |
| Operating Profit | 6 | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| OPM % | 12% | 5% | 6% | 2.3% | -3.1% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| Other Income | 2 | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 |
| Interest | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 6 | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Tax % | -111% | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | — |
| Net Profit | 13 | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| EPS in Rs | 2.91 | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves | -15 | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| Borrowings | 7 | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 |
| Other Liabilities | 45 | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 |
| Total Liabilities | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Fixed Assets | 9 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 |
| CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 71 | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 |
| Total Assets | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
Cash Flow
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 5 | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Investing | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 |
| Financing | -3 | 0 | -6 | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 |
| Net Cash Flow | 2 | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Free Cash Flow | 5 | 32 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| CFO/OP | 89 | 338 | -99 | 229 | 239 | -132 | -32 | 344 | -328 | -56 | 847 | -59 |
Ratios
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory Days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Days Payable | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash Conversion Cycle | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working Capital Days | -20 | -20 | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
| ROCE % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bharat Immunological & Biological Corporation insights
62 extracted metrics + investor summaries across FY08–FY23.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Director
9 Feb - Ms. Ching Chun Yang resigned as Independent Director of D-Link India effective 5 February 2026; ceases committee memberships. 9 Feb - Ms. Ching Chun Yang resigned as Independent Director of D-Link India effective 5 February 2026; ceases committee memberships.
3
Financial Results For The Quarter Ended December 31, 2025
5 Feb - Board approved Q3 results; customs demand ₹611.49 lakh (19 Jan 2026); director resigned 5 Feb 2026. 5 Feb - Board approved Q3 results; customs demand ₹611.49 lakh (19 Jan 2026); director resigned 5 Feb 2026.
4
Announcement under Regulation 30 (LODR)-Resignation of Director
5 Feb - Approved Q3/9M results; Independent director resigned; Customs demand ₹611.49 lakh (19 Jan 2026). 5 Feb - Approved Q3/9M results; Independent director resigned; Customs demand ₹611.49 lakh (19 Jan 2026).
5
Board Meeting Outcome for Outcome Of The Board Meeting
5 Feb - Approved Q3/9M results; Rs611.49 lakh customs demand; Ms. Ching Chun Yang resigned effective 05-Feb-2026. 5 Feb - Approved Q3/9M results; Rs611.49 lakh customs demand; Ms. Ching Chun Yang resigned effective 05-Feb-2026.
Frequently Asked Questions about Bharat Immunological & Biological Corporation
What does Bharat Immunological & Biological Corporation Ltd do?
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
Where is Bharat Immunological & Biological Corporation Ltd (524663) listed?
Bharat Immunological & Biological Corporation Ltd trades as BHARATIMMUNOLOGICALSBIOLOGICALSCORPORATIONLTD on the NSE and under code BIBCL on the BSE.
Which sector does Bharat Immunological & Biological Corporation Ltd belong to?
Bharat Immunological & Biological Corporation Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd has a market capitalisation of ₹64.75 Cr, which places it in the Small Cap band.
What is the PE ratio of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd trades at a PE ratio of -3.60, on earnings per share of ₹0, against a book value of ₹-7.54 per share.
What is the 52-week high and low of Bharat Immunological & Biological Corporation Ltd?
Over the last 52 weeks Bharat Immunological & Biological Corporation Ltd has traded between ₹14.1 and ₹22.61.
What is the Return on Equity (ROE) of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd reported a return on equity of -19.43%. Its debt-to-equity ratio is 0.80.
Company Information
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
Website bibcol.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524663.md for Bharat Immunological & Biological Corporation Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.